Evidence map›Paper›PMID 32565981›Full record

ArticleOncology letters2020

Germline mutations in

Haibo Zhu, Yazhou Miao, Yutao Shen, Jing Guo, Weiyan Xie, Sida Zhao, Wei Dong, Yazhuo Zhang, Chuzhong Li

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Haibo ZhuDepartment of Neurosurgery, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing 100070, P.R. China.
Yazhou MiaoCell Laboratory, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, P.R. China.
Yutao ShenCell Laboratory, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, P.R. China.
Jing GuoCell Laboratory, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, P.R. China.
Weiyan XieCell Laboratory, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, P.R. China.
Sida ZhaoCell Laboratory, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, P.R. China.
Wei DongCell Laboratory, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, P.R. China.
Yazhuo ZhangDepartment of Neurosurgery, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing 100070, P.R. China.
Chuzhong LiDepartment of Neurosurgery, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing 100070, P.R. China.
Capital Medical University · CNBeijing Institute of Neurosurgery · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pituitary adenoma and meningioma are two of the most common benign tumors in the central nervous system. Pituitary adenoma associated with meningioma (PAM) is a rare disease, the tumorigenesis of which remains unclear. Therefore, the aim of the present study was to investigate the tumorigenesis of PAM. A total of 8,197 patients with pituitary adenoma were analyzed. Furthermore, the clinical data of 57 patients with PAM were compared with patients with multiple endocrine neoplasia 1 (MEN-1) syndrome. Whole exome sequencing (WES) was performed on 23 samples from patients with PAM and the germline mutation was verified by Sanger sequencing. The age of tumor penetrance (age of patients at diagnosis) for PAM was significantly higher than that for patients with MEN-1. Compared with MEN-1 patients, there was a significant association between PAM and female sex (P=0.004). Clonal analysis and phylogenetic tree construction suggested that the pituitary adenoma and meningioma in PAM don't originate from a common progenitor. WES revealed that 5/23 PAM samples had the recurrent germline mutation

Indexed as

germline mutationMEN1PAM

Identifiers

PMID32565981
PMCPMC7285847
OpenAlexW3024861346

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.